Clinical Trial Update: A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating PN20 to prevent chemotherapy-induced thrombocytopenia in patients with lymphoma or solid tumors; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• PN20

Snippet

Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. | Conditions: Thrombocytopenia | Phase 1 | Status: COMPLETED